Financings Of The Fortnight Not Seeing A Trickle-Down Investment Effect From Last Year’s IPOs
This article was originally published in The Pink Sheet Daily
Executive Summary
The 2013 life sciences IPO boom does not necessarily augur more of the same for those biotechs now lining up to go public. Plus financing news from Juno Therapeutics, GlycoMimetics, Ultragenyx and Alkermes.